TD Cowen projects that with Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) continuing their dominance, global sales of the GLP-1 ...

Septerna discontinues phase 1 clinical trial of SEP-786; plans to advance next-generation oral small molecule PTH1R agonist: South San Francisco, California Friday, February 21, 2 ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in two upcoming ...

Chimeric antigen receptor T-cell therapy has been really instrumental in how we treat patients with myeloma. It has really changed the face of how we treat this disease, so since 2021, we've had two ...

The main focus right now in the myeloma paradigm of treatment is, okay, how do we harness the best power of CAR-T? We're doing it later in the treatment of myeloma. We've tried to move it earlier, and ...

Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...

Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are ...

The decision to halt the trial was made despite the lack of serious adverse events or indications of liver injury, cholestasis, or hemolysis in trial participants. Septerna's CEO, Jeffrey Finer, ...

Striatal dopamine (DA) release regulates reward-related learning and behavioural activation and is believed to consist of a short-lived phasic and continuous tonic component. Here, we build a ...

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Mr. Shinichi Tamura, Mr. Tomohiro Tohyama and Mr. Kuniaki Kaga to retire from the Board of Directors ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...